TCTMD’s Top 10 Most Popular Stories for April 2019
FDA approvals and alerts dominated the list, along with stories on informed consent, PCI in the elderly, left main CABG, and more.
The US Food and Drug Administration approval of the Lotus Edge TAVR device was the top story for April 2019, but the list was otherwise dominated by stories relating to coronary interventions and primary prevention of CVD. Two FDA safety alerts helped round out this month’s top 10.
The decision marked the approval of the first fully repositionable and retrievable TAVR device in the United States.
Shared decision-making may be upping patients’ satisfaction but not their knowledge of procedural risks and benefits, experts say.
The FDA says there’s been one serious injury, but no deaths, due to balloons deflating, fragmenting, or detaching.
“We shouldn’t age discriminate,” an expert agreed, but he cautioned against reading too much into the unadjusted outcomes data.
The improvement likely isn’t due to changes in the surgery but rather to greater use of optimal medical therapy, say experts.
Concerns that omega-6 PUFAs may be pro-inflammatory and prothrombotic should be allayed, investigators say.
Eating breakfast may be a simple way to promote cardiovascular health, a researcher says.
The study helps identify at-risk patient populations, which is important as TAVR moves into lower-risk cohorts, an expert says.
A new analysis hints that trials should enroll patients with Lp(a) levels of > 100 mg/dL and more modest cuts will be meaningful.
The neurointerventional device for intracranial stenosis ups the risk of stroke and death when used for nonapproved indications.